Health
Moderna and Merck advance personalized mRNA cancer vaccine following trial success
The successful late-stage trial data for intismeran autogene marks a milestone for personalized mRNA cancer vaccines, shifting the field from decades of failure toward new combination therapies for solid tumors.
AI · grounded7 of 8 claims single-sourced